The first and second phase of the BBIBP-CorV vaccine for Covid-19 have been found to be safe and produce an immune response, according to the latest study published in The Lancet Infectious Diseases Journal.
The candidate vaccine was developed by China National Biotec Group (CNBG) and the Beijing Institute of Biological Products. The study, based on the first and second phases, was conducted by researchers at CNBG, Chinese disease control authorities and other research institutes.
The study indicated that the results of the Phase 3 trial of the BBIBP-CorV vaccine currently underway in Abu Dhabi will provide information on whether this vaccine is safe and effective against SARS-CoV-2 infection, and how long to maintain the protective effect. . The human experiment is taking place in the United Arab Emirates through a partnership between Sinopharm CNBG and Group 42 (G42) based in Abu Dhabi under the supervision of the Abu Dhabi Ministry of Health.
Promising result for the elderly
In the Phase 1 dose increase trial, the researchers' study found that “the older age group had lower rates of desired adverse events than younger adults: the overall rates of adverse events within 28 days after vaccination were 34 (47 per cent) of 72 participants in the group were between the ages of 18 and 59, compared to 14 (19 percent) of the 72 participants aged 60 and over. "
After the first shot of the vaccine has been taken, the second dose is given 21 days later. An early phase II trial of BBIBP-CorV vaccine in healthy adults aged 18 to 59 years evaluated the effect of shortening the interval between two doses from 28 days to 14 days or 21 days on vaccine immunity. The study found that the vaccine was the most immune when given in a 21-day period, but its immune capacity significantly decreased when the interval was reduced to 14 days, indicating that the interval could not be shorter than three weeks.
These results were reported to come from a combined Phase I and Phase II trial of more than 600 healthy adults conducted between April 29 and July 30. The current study is the second to report on interim safety and immunity outcomes of an inactivated SARS vaccine.